# **Review** Article

# A System Review and Meta-Analysis of Canaloplasty Outcomes in Glaucoma Treatment in Comparison with Trabeculectomy

### Bing Zhang, Jie Kang, and Xiaoming Chen

Department of Ophthalmology, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu 610041, China

Correspondence should be addressed to Xiaoming Chen; chenxm58@163.com

Received 22 December 2016; Accepted 1 March 2017; Published 30 April 2017

Academic Editor: Gianluca Scuderi

Copyright © 2017 Bing Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Purpose.* This system review studied the efficiency and safety of canaloplasty (CP) and compared the outcomes between CP and trabeculectomy (TE). *Methods.* Literatures were searched in PubMed and EMBASE. The meta-analysis was conducted on the postoperative outcomes in CP and then on the differences of outcomes between CP and TE. *Results.* In the meta-analysis, IOP decreased by 9.94 (95% CI 8.42 to 11.45) mmHg with an average AGM reduction of 2.11 (95% CI 1.80 to 2.42) one year after CP. The IOP reduction was significantly higher after TE than after CP, with an average difference of 3.61 (95% CI 1.69 to 5.53) mmHg at 12 months postoperationally. For complications, the incidence of hyphema was significantly higher in CP and the Descemet membrane detachment was just reported in CP, with an incidence of 3%. However, the incidence was significantly lower in CP of hypotony and of choroidal effusion/detachment. Meanwhile, suprachoroidal hemorrhage and bleb needling were only reported in TE. *Conclusions.* CP was less effective in IOP reduction than TE, but CP was able to achieve similar postoperative success rates and reduce the number of AGMs likewise. CP was also associated with lower incidence of complications. More high-quality researches are needed in the future to verify our findings in this system review.

#### **1. Introduction**

Intraocular pressure (IOP) is by now the most proven treatable factor in glaucoma, and lowering IOP has long been associated with slowing the damages by glaucoma [1, 2]. Trabeculectomy (TE), since firstly being introduced in the 1960s, has remained the standard surgery of IOP control in glaucoma [3]. However, the relatively high incidence of complications of TE [3, 4] has encouraged the development of new surgery methods.

Canaloplasty (CP) was a nonpenetrating surgery (NPS) performed with a microcatheter (iTrack; iScience Surgical Corp.). During CP, the Schlemm canal is expanded circum-ferentially injecting a small amount of high-weight molecular viscoelastic agent with iTrack and then a suture loop is placed to apply tension to the trabecular meshwork when iTrack is retracted [5]. CP has been performed as one major NPS in open-angle glaucoma treatment for years. However, no system review of CP to evaluate its efficiency and complications in the treatment of glaucoma has been published by now as far as we know. This study firstly made a system review of

CP and then compared the efficiency and complications between CP and TE.

# 2. Methods

This research was accorded to a predetermined protocol based on the Cochrane Handbook for Systematic Reviews of Interventions [6]. Review board approval was not required as no patients were enrolled.

2.1. Eligibility Criteria. Studies which met the following criteria were considered eligible: (1) participants diagnosed with glaucoma regardless of age, sex, or race, studies limited in patients with another failed antiglaucoma surgery were excluded; (2) interventions, included but not limited to CP, with or without phacoemulsification; (3) research types, both prospective and retrospective studies, excluding case reports and reviews; (4) outcomes: included but not limited to IOP, the follow-up was at least 6 months; (5) for literatures with overlapping data, only the one with the largest sample and then the longest follow-up was included.



FIGURE 1: Flow diagram for study selection.

2.2. Search Strategies. PubMed and EMBASE were searched for literatures published up to April 1, 2016, in any language with the following strategies: ((circumferential OR 360) AND (viscocanalostomy OR viscodilat\*)) OR canaloplasty. No unpublished studies were searched. After removing duplicate records, two reviewers (Bing and Jie) independently decided whether a study met the inclusion criteria; exclusion reasons were given to every literature not included.

2.3. Outcome Measures. The primary outcomes were the changes in IOP and the number of antiglaucoma medications (AGMs). The secondary outcomes were the complete and qualified successful rates and the incidence of adverse events. A complete success is defined as that a confirmed IOP is less than a given level without any AGMs; a qualified success is defined as that a confirmed IOP is less than a given level without AGMs [7]. The outcomes and research information were extracted by two researchers (Bing and Jie) independently.

2.4. Statistical Analysis. The meta-analysis was conducted with the software Review Manager V5.2 (Cochrane Collaboration). The changes in IOP and AGMs after CP were metaanalyzed in three subgroups, CP standalone, CP with phacoemulsification (PCP), and CP mixed (the former two subgroups mixed in the original papers). The mean between-group difference (MeD) of reductions in IOP and AGMs and the odds ratios (ORs) of the success rates and the incidence of complications were analyzed between CP and TE in two subgroups, standalone CP versus standalone TE and PCP versus phacotrabeculectomy (PTE). The random effects model was applied in most cases as the heterogeneity was considered present in the enrolled studies for clinical and study differences.

2.5. Sensitivity Analysis, Publication Bias Analysis, and Quality Assessment. Sensitivity analysis was performed for IOP and AGM reductions in CP by deleting the following subgroups: (a) all retrospective studies and (b) studies with small weight (less than the average weight). The publication bias was analyzed with the asymmetry of funnel plot [8]. Neither sensitivity analysis nor funnel plot analysis was conducted in the meta-analysis outcomes between CP and TE, with only 6 literatures enrolled. The quality assessment was performed in the meta-analysis between CP and TE; 1 randomized controlled trial (RCT) was analyzed with the risk of bias table according to the Cochrane Handbook for Systematic Reviews of Interventions [6] and the other 5 non-RCTs were analyzed with the Newcastle-Ottawa Quality

TABLE 1: Characteristics and baseline information of included literatures.

	Study type	Age, mean (SD)	Male%	Eyes at baseline	POAG%	Baseline IOP, mean (SD)	Baseline AGMs, mean (SD)
Canaloplasty standalone							
Ayyala et al. [10]	Retrospective	68.3 (10.0)	52	33	NA	21.2 (6.6)	2.5 (0.8)
Barnebey [11]	Retrospective	68.2 (13.1)	55	20	100	23.4 (4.3)	2.2 (1.2)
Brandao et al. [12]	Prospective	71.3 (7.3)	41	19	74	24.6 (5.3)	2.5 (0.8)
Bruggemann and Muller [13]	Retrospective	62.7 (NA)	52	21	100	28.8 (9.6)	2.9 (1.0)
Brusini [14]	Prospective	63.5 (14.0)	NA	214	74	29.4 (7.9)	3.3 (0.9)
Gandolfi et al. [15]	Retrospective	NA	67	24	67	26.0 (4.0)	2.7 (3.3)
Grieshaber et al. [16]	Prospective	49.8 (15.7)	43	60	100	45.0 (12.1)	NA
Grieshaber et al. [17]	Prospective	70.8 (8.4)	49	47	100	26.8 (5.2)	2.8 (0.5)
Grieshaber et al. [18]	Prospective	71.8 (8.8)	41	22	100	27.1 (5.3)	2.9 (0.6)
Kalin-Hajdu et al. [19]	Retrospective	40.0 (19.2)	NA	19	0	30.4 (8.4)	3.7 (0.8)
Lewis et al. [20] (CP)	Prospective	67.6 (11.6)	47	103	89	23.5 (4.5)	1.9 (0.8)
Lommatzsch et al. [7]	Retrospective	40.7 (21.8)	25	14	0	27.1 (12.3)	2.7 (1.1)
Lopes-Cardoso et al. [21] (CP)	Prospective	73.4 (6.0)	66	11	37	24.5 (5.1)	3.4 (0.5)
Matlach et al. [22]	RCT	66.5 (11.3)	60	30	43	23.7 (5.1)	2.6 (1.6)
Matthaei et al. [23] (CP)	Retrospective	65.2 (12.4)	46	33	87	18.5 (6.3)	2.3 (1.2)
Moelle et al. [24]	Retrospective	62 (9)	42	26	54	21.1 (5.8)	2.5 (1.8)
Seuthe et al. [25]	Retrospective	66.7 (11.4)	NA	417	86	20.9 (3.5)	3.5 (0.9)
Thederan et al. [26]	Retrospective	72.9 (5.2)	64	22	68	23.7 (7.6)	3.1 (1.2)
Voykov et al. [27]	Retrospective	60 (11)	45	20	75	25.7 (6.6)	3.4 (0.5)
Wang et al. [28]	Retrospective	39.1 (13.8)	77	17	NA	24.7 (8.7)	2.4 (1.7)
Xin et al. [29]	Prospective	38 (12.8)	65	17	100	29.9 (8.2)	2.9 (0.9)
Canaloplasty with phacoemulsification							
Arthur et al. [30]	Retrospective	76.1 (8.3)	56	32	84	18.2 (5.1)	1.3 (0.7)
Lewis et al. [20] (PCP)	Prospective	67.6 (11.6)	47	30	89	23.5 (5.2)	1.5 (1.0)
Lopes-Cardoso et al. [21] (PCP)	Prospective	73.4 (6.0)	66	24	37	19.8 (6.8)	3.3 (0.5)
Matlach et al. [31]	Retrospective	72.9 (5.7)	47	19	47	28.3 (4.1)	2.8 (1.1)
Matthaei et al. [23] (PCP)	Retrospective	65.2 (12.4)	46	13	87	17.5 (4.2)	2.5 (1.3)
Rekas et al. [32]	RCT	74.6 (8.9)	59	29	83	19.0 (6.9)	2.6 (0.7)
Schoenberg et al. [33]	Retrospective	66.8 (8.5)	67	36	94	19.5 (5.7)	NA
Canaloplasty with or without phacoemulsification, mixed results							
Alobeidan and Almobarak [34]	Retrospective	53.4 (15.0)	60	105	67	19.0 (6.7)	2.6 (1.3)
Fujita et al. [35]	Retrospective	71.7 (8.5)	NA	11	100	23.4 (5.5)	2.8 (0.6)
Rekas et al. [36]	Prospective	69.3 (11.4)	40	10	90	19.1 (3.4)	2.2 (1.1)

AGM: antiglaucoma medication; CP: independent canaloplasty subgroup in corresponding literature; NA: data not available; PCP: phacocanaloplasty subgroup in corresponding literature; POAG: primary open-angle glaucoma; RCT: randomized controlled trials.

Assessment Scale [9]. All analyses in this part were performed by two researchers (Bing and Jie) independently.

## 3. Results

3.1. Literatures Selection and Characteristics of the Enrolled Studies. 210 records returned from the initial literature search after deduplicating 136 records. 28 records were included in the quantitative analysis, and the other 182 did not meet the eligibility criteria as the process shown in Figure 1. An update of the literature search was made in February 3, 2017, and no new study was enrolled to the quantitative analysis. Table 1

shows the descriptions of the enrolled 28 literatures. 1498 eyes were enrolled at baseline totally, 78% of which were diagnosed with primary open-angle glaucoma (POAG). The average age of patients at baseline was  $62.7 \pm 15.4$  years in the independent CP subgroup and  $71.2 \pm 9.6$  years in the PCP subgroups. The average baseline IOP was  $25.1 \pm 8.5$  mmHg with  $3.04 \pm 1.18$  AGMs in CP standalone subgroup, and the mean baseline IOP was  $20.7 \pm 6.4$  mm Hg with  $2.23 \pm 1.14$  AGMs in the PCP subgroup.

3.2. The Efficiency of CP. The reduction of IOP in all subgroups at 6 months was 10.69 (95% CI 8.96 to12.43)

TABLE 2: Meta-analysis outcomes of reductions in IOP and antiglaucoma medications (AGMs) at 6 and 12 months postoperationally.

		IOP reduction (95% CI) mmHg	AGMs, reduction (95% CI)
Standalone canaloplasty	6 months	12.01 (9.77, 14.24)	2.01 (1.51, 2.50)
	12 months	11.38 (9.43, 13.34)	2.16 (1.79, 2.53)
Phacocanaloplasty	6 months	8.32 (5.36, 11.27)	2.03 (1.36, 2.70)
	12 months	8.14 (4.83, 11.46)	2.04 (1.15, 2.92)

TABLE 3: Incidence of complications of canaloplasty.

Complications	Incidence% (events/pooled eyes)
Hyphema (blood layer > 1 mm)	24.9 (304/1221)
Hypotony < 5 mmHg	8.6 (94/1091)
Descemet membrane detachment	3.1 (37/1185)
Detectable conjunctival bleb	1.9 (17/899)

		CP/PCP			TE/PTE			Mean difference		Me	n differen	20	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% Cl		IV, ra	ndom, 95%	5 Cl	
CP versus TE standalone (IOP reduction mmHg)													
Ayyala et al. 2011	7.4	8.22009732	33	11.8	11.14271062	46	16.8%	-4.40 [-8.67, -0.13]		-	_		
Bruggemann and Muller 2012	15.95	10.11648654	21	24.22	14.1480529	48	9.6%	-8.27 [-14.16, -2.38]					
Matlach et al. 2015	9.9	5.77061522	30	11.4	6.04152299	32	29.8%	-1.50 [-4.44, 1.44]					
Thederan et al. 2014	7.9	8.71739066	22	10.8	12.78632082	22	8.1%	-2.90 [-9.37, 3.57]		-			
Subtotal (95% CI)			106			148	64.3%	-3.65 [-6.42, -0.88]					
Heterogeneity: $\tau^2 = 2.61$ ; $\chi^2 = 4.4$ Test for overall effect: $z = 2.59$ ( $l$	44, df = 3 (F P = 0.010)	$P = 0.22$ ; $I^2 = 32\%$											
PCP versus PTE (IOP reduction mmHg)													
Matlach et al. 2013	15.7	4.60651712	19	18.3	6.3513778	20	23.4%	-2.60 [-6.07, 0.87]					
Schoenberg 2015	5.4	7.20069441	36	11.8	14.81890684	41	12.3%	-6.40 [-11.51, -1.29]			-		
Subtotal (95% CI)			55			61	35.7%	-4.02 [-7.62, -0.42]					
Heterogeneity: $\tau^2 = 2.25$ ; $\chi^2 = 1$ . Test for overall effect: $z = 2.19$ (1)	45, df = 1 ( P = 0.03)	$P = 0.23$ ; $I^2 = 31$	%										
Total (95% CI)			161			209	100.0%	-3.61 [-5.53, -1.69]		-	-		
Heterogeneity: $\tau^2 = 0.96$ ; $\chi^2 = 5$	.99, df = 5 (	$(P = 0.31); I^2 = 16$	5%						10	-			10
Test for overall effect: $z = 3.69$ (1	P = 0.0002)								-10	-5	0	5	10
Test for subgroup differences: $\chi^2$	= 0.03, df	$= 1 P = 0.87); I^2 =$	= 0%						Fa	vours TE/PT	E l	Favours CP/P	CP
Ci. 1		CP/PCP			TE/PTE			Mean difference		Me	an differer	ice	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% Cl		IV, r	andom, 95	% Cl	
CP versus TE standalone (AGMs reduction)													
Ayyala et al. 2011	1.84	1.23239604	33	2.33	0.94847246	46	27.9%	-0.49 [-0.99, 0.01]					
Bruggemann and Muller 2012	2.9	1	21	2.8	1.1	48	26.9%	0.10 [-0.43, 0.63]			-		
Matlach et al. 2015	1.8	2	30	3	1.22065556	32	17.6%	-1.20 [-2.03, -0.37]		-	-		
Thederan et al. 2014	2.2	1.7691806	22	2.07	1.72046505	22	13.4%	0.13 [-0.90, 1.16]			-		
Subtotal (95% CI)			106			148	85.7%	-0.36 [-0.91, 0.19]					
Heterogeneity: $\tau^2 = 0.19$ ; $\chi^2 = 7$ Test for overall effect: $z = 1.27$ (F	.90, df = 3 = 0.20)	$(P = 0.05); I^2 = 6$	2%										
PCP versus PTE (AGMs reduction	ı)												
Matlach et al. 2013	1.8	1.86010752	20	2.3	1.26491106	20	14.3%	-0.50 [-1.49, 0.49]					
Subtotal (95% CI)			20			20	14.3%	-0.50 [-1.49, 0.49]					
Heterogeneity: not applicable													
Test for overall effect: $z = 3.99$ (F	9 = 0.32)												
Total (95% CI)			126			168	100.0%	-0.37 [-0.83, 0.08]					
Heterogeneity: $\tau^2 = 0.13$ ; $\chi^2 = 8$	01, df = 4 (	$(P = 0.09); I^2 = 50$	0%							1	1	1	
Test for overall effect: $z = 1.60$ (F	= 0.11)								-4	-2	U	2	4
Test for subgroup differences: $\chi^2$	= 0.06, df =	= 1 ( $P = 0.81$ ); $I^2$ =	= 0%						Fa	yours TE/PT	E	Favours Cl	P/PCP

FIGURE 2: Comparison of the reductions in IOP and antiglaucoma medications (AGMs) between canaloplasty (CP) and trabeculectomy (TE) (PCP = phacocanaloplasty, PTE = phacotrabeculectomy).

#### Journal of Ophthalmology

	CP/F	СР	TE/I	PTE		Odds ratio		Odd	s ratio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, random, 95%	Cl	M-H, rand	om, 95% Cl	
Complete success <18 mmHg										
Matlach et al. 2015	13	23	24	31	38.1%	0.38 [0.12, 1.23]			+	
Thederan et al. 2014	12	22	11	22	37.8%	1.20 [0.37, 3.92]				
Matlach et al. 2013	9	15	15	19	24.1%	0.40 [0.09, 1.81]			<u> </u>	
Total (95% CI)		60		72	100.0%	0.59 [0.28, 1.27]		-		
Total events	34		50							
Heterogeneity: $\tau^2 = 0.04$ ; $\chi^2 = 2.17$ , df = 2 Test for overall effect: $Z = 1.34$ ( $P = 0.18$ )	(P = 0.34); I	<sup>2</sup> = 8%								
Complete Success < 21 mmHg + 20% IO	$P \downarrow (Matlach$	2015 & T	heredan 2014) or	+ 30% IOP $\downarrow$	(Matlach et a	al. 2013)				
Matlach et al. 2015	14	23	24	31	42.7%	0.45 [0.14, 1.49]			+	
Thederan et al. 2014	10	22	10	22	29.1%	1.00 [0.31, 3.28]			-	
Matlach et al. 2013	9	15	15	19	28.2%	0.40 [0.09, 1.81]				
Total (95% CI)		60		72	100.0%	0.60 [0.29, 1.24]		-		
Total events	33		49							
Heterogeneity: $\chi^2 = 1.20$ , df = 2 ( <i>P</i> = 0.55)	5); $I^2 = 0\%$									
Test for overall effect: $Z = 1.39$ ( $P = 0.17$ )										
Qualified Success <18 mmHg										
Matlach et al. 2015	22	23	31	31	28.3%	0.24 [0.01, 6.12]	$\leftarrow$			
Thederan et al. 2014	17	22	13	22	71.7%	2.35 [0.63, 8.73]		-		
Matlach et al. 2013	15	15	19	19		Not estimable				
Total (95% CI)		60		72	100.0%	1.23 [0.16, 9.39]				
Total events	54		63							
Heterogeneity: $\tau^2 = 1.05$ ; $\chi^2 = 1.66$ , df = 1 Test for overall effect: <i>Z</i> = 0.20 ( <i>P</i> = 0.84)	P = 0.20; I	$!^2 = 40\%$								
Qualified Success < 21 mmHg + 20% IOI	$P \downarrow (Matlach$	2015 & T	heredan 2014) or	+ 30% IOP ↓	(Matlach et a	al. 2013)				
Matlach et al. 2015	23	23	30	31	13.3%	2.31 [0.09, 59.35]				
Thederan et al. 2014	16	22	13	22	86.7%	1.85 [0.52, 6.55]		-		
Matlach et al. 2013	15	15	19	19		Not estimable				
Total (95% CI)		60		72	100.0%	1.91 [0.59, 6.19]		-		
Total events	54		62							
Heterogeneity: $\chi^2 = 0.02$ , df = 1 ( $P = 0.90$	0); $I^2 = 0\%$						H		+ +	I
Test for overall effect: $Z = 1.08$ ( $P = 0.28$ )							0.01	0.1	1 10	100
								More success in TE/PTE	More success in	CP/PCP

FIGURE 3: Comparison of success rates between canaloplasty (CP) and trabeculectomy (TE) (independent CP versus TE in Matlach et al. [22] and Thederan et al. [26]; PCP versus PTE in Matlach [31]; PCP = phacocanaloplasty, PTE = phacotrabeculectomy).

mmHg with 2.03 (95% CI 1.69 to 2.37) less AGM use and at 12 months was 9.94 (95% CI 8.42 to 11.45) mmHg with 2.11 (95% CI 1.80 to 2.42) less AGM use. Table 2 shows more information of the meta-analysis results (detailed information and the forest plots in Online Resource Figures 1–4 in Supplementary Material available online at https://doi.org/ 10.1155/2017/2723761).

*3.3. The Complications of CP.* Table 3 summarizes the incidence of complications of CP (included PCP). The most common one was hyphema; hyphema (blood layer > 1 mm) could be observed in about every four enrolled eyes (24.9%). The incidence of the other complications in CP is shown in Table 3.

#### 3.4. Comparison of CP and TE

*3.4.1. Reductions in IOP and AGMs.* The meta-analysis results of the MeDs between TE and CP of the reductions in IOP and AGMs at 12 months after surgery are shown in Figure 2 (data at 6 months used in Bruggemann and Muller [13]). TE was more efficient in IOP control than CP, with a MeD of 3.61 (95% CI, 1.695.53) mmHg. However, no significant difference was

found in the reduction of AGMs between CP and TE, with a MeD of -0.37 (95% CI -0.830.08).

*3.4.2. The Success Rates.* The complete and qualified success rates were compared between CP and TE at 12 months in three studies [22, 26, 31] as shown in Figure 3. No significant difference in the success rates was found between CP and TE in all comparisons shown in Figure 3.

3.4.3. The Complications. The complications were compared between CP and TE in five researches [10, 22, 26, 31, 33] with ORs as shown in Figure 4. The hyphema was more prevalent in CP with an OR of 9.24 (95% CI, 3.09 to 27.60). The Descemet membrane detachment was only observed in CP with a reported incidence of 3%. The suprachoroidal hemorrhage and bleb needling were only reported in TE with incidences of 2.3% and 10.9%, respectively. TE was with significantly higher incidences in hypotony and the choroidal effusion/detachment. No significant difference was found in the incidence of conjunctiva leakage (OR 0.72, 95% CI 0.16 to 3.14).

	CP/P	СР	TE/I	PTE		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H, random, 95% C	M-H, random, 95% Cl
Hyphema					-		
Ayyala et al. 2011	7	33	1	46	25.9%	12.12 [1.14, 104.03]	$  \longrightarrow$
Matlach et al. 2013	4	19	1	20	22.8%	5.07 [0.51, 50.21]	
Matlach et al. 2015	7	30	1	32	25.6%	9.43 [1.08, 82.11]	
Schoenberg et. al 2015	10	36	0	41	14.5%	32.89 [1.85, 585.03]	$ \longrightarrow $
Thederan et. al 2014	1	22	0	22	11.3%	3.14 [0.12, 81.35]	
Total (95% CI)		140		161	100.0%	9.24 [3.09, 27.60]	
Total events	29		3				
Heterogeneity: $\tau^2 = 0.00$ ; Test for overall effect: $z = Descemet membrane$	$\chi^2 = 1.55$ = 3.98 (P	5, df = 4 < 0.000	4 (P = 0.82 01)	2); $I^2 = 0$	9%		
Avvala et al. 2011	1	33	0	46	33.4%	4.29 [0.17, 108,71]	
Matlach et al. 2015	1	30	0	32	33.2%	3.31 [0.13, 84.32]	
Schoenberg et al. 2015	1	36	0	41	33.4%	3 51 [0 14 88 82]	
Total (95% CI)	1	99	0	119	100.0%	3.68 [0.57, 23.80]	
Total events	3	,,	0		1001070		
Heterogeneity: $\tau^2 = 0.00$ :	$v^2 = 0.01$	l. df = 2	P = 0.9	(a): $I^2 = 0$	0%		
Test for overall effect: <i>z</i> = <i>Hypotony</i>	= 1.37 (P	= 0.17)	5 (1 015).	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	.,.		
Matlach et al. 2013	0	19	3	20	9.3%	0.13 [0.01, 2.66]	
Matlach et al. 2015	6	30	12	32	65.2%	0.42 [0.13, 1.31]	
Schoenberg et al. 2015	0	36	2	41	9.1%	0.22 [0.01, 4.66]	
Thederan et al. 2014	1	22	4	22	16.5%	0.21 [0.02, 2.09]	
Total (95% CI)		107		115	100.0%	0.32 [0.13, 0.80]	
Total events	7		21				
Heterogeneity: $\tau^2 = 0.00$ ; Test for overall effect: $z =$	$\chi^2 = 0.75$ = 2.45 (P	5, df = 3 = 0.01)	P = 0.86	$(5); I^2 = 0$	%		
Conjunctiva leakage							
Matlach et al. 2015	3	30	3	32	77.2%	1.07 [0.20, 5.79]	
Thederan et al. 2014	0	22	2	22	22.8%	0.18 [0.01, 4.02]	
Total (95% CI)		52		54	100.0%	0.72 [0.16, 3.14]	
Total events	3		5	2			
Heterogeneity: $\tau^2 = 0.00$	; $\chi^2 = 0.9$	9, df =	1 (P = 0.3)	2); $I^2 = 0$	)%		
Test for overall effect: $z =$	= 2.44 (P =	= 0.66)					
Choroidal effusion or detachment							
Ayyala et al. 2011	0	33	8	46	21.9%	0.07 [0.00, 1.22]	
Matlach et al. 2013	0	19	2	20	19.0%	0.19 [0.01, 4.22]	
Matlach et al. 2015	1	30	4	32	36.0%	0.24 [0.03, 2.29]	
Schoenberg et al. 2015	1	36	1	41	23.1%	1.14 [0.07, 18.96]	
Total (95% CI)		118		139	100.0%	0.25 [0.06, 0.97]	
lotal events	2	. 10	15	-> -2			
Heterogeneity: $\tau^2 = 0.00$ ; Test for overall effect: $z =$	$\chi^2 = 2.03$ = 2.01 (P	3, df = 3 = 0.04)	3(P=0.5)	$(7); I^2 = 0$	1%		
Suprachoroidal hemorrh	age						_
Ayyala et al. 2011	0	33	1	46	50.0%	0.45 [0.02, 11.46]	
Schoenberg et al. 2015	0	36	1	41	50.0%	0.37 [0.01, 9.37]	
Total (95% CI)		69		87	100.0%	0.41 [0.04, 4.02]	
Total events	0		2				
Heterogeneity: $\tau^2 = 0.00$ ;	$\chi^2 = 0.01$	1, df = 1	1 (P = 0.93)	$(3); I^2 = 0$	)%		
Test for overall effect: <i>z</i> = <i>Bleb needling</i>	= 0.77 (P	= 0.44)					
Ayyala et al. 2011	0	33	7	46	36.0%	0.08 [0.00, 1.43]	
Matlach et al. 2015	0	30	1	32	28.8%	0.34 [0.01, 8.78]	
Schoenberg et al. 2015	0	36	5	41	35.2%	0.09 [0.00, 1.70]	
Total (95% CI)		99		119	100.0%	0.13 [0.02, 0.72]	
Total events	0		13				
Heterogeneity: $\tau^2 = 0.00$ ;	$\chi^2 = 0.53$	3, df = 2	P = 0.77	$(7); I^2 = 0$	%		
Test for overall effect: $z =$	= 2.33 (P	= 0.02)					0.01 0.1 1 10 100
							More likely in TE/PTE More likely in CP/PCP

FIGURE 4: Comparison of complications between canaloplasty (CP) and trabeculectomy (TE).

3.4.4. Sensitivity Analysis. In sensitivity analysis, the difference between before and after removing all retrospective studies in the IOP reductions was 14% at 6 months and 17% at 12 months; the corresponding difference in the AGM reductions was 5% at 6 months and 5% at 12 months. The difference between before and after removing the small weight studies in the IOP reduction was -3% at 6 months and -9% at 12 months; the corresponding change in the AGM reduction was 4% at 6 months and 0% at 12 months (detailed data in the Online Resource Table 1). The publication bias analysis and the quality assessment were given in the discussion part.

# 4. Discussion

As far as we know, this was the first system review of CP in glaucoma control. At one year after CP, IOP decreased by 9.94 (95% CI 8.42 to 11.45) mmHg with 2.11 (95% CI 1.80 to 2.42) less AGM use. TE was shown to be more efficient in IOP control than in CP, with 3.61 (95% CI, 1.69 to 5.53) mmHg more IOP reduction at 12 months postoperationally. Our finding confirmed the conclusion of Rulli's metaanalysis that NPS was less effective than TE in decreasing IOP and also supported the opinion that canal surgery was less effective than TE in IOP control [3]. However, no significant difference between CP and TE was found in the AGM reduction and in the complete or qualified success rates at 1 year after surgery. CP was able to achieve similar postoperative success rates and reduce the number of the AGMs likewise.

In CP, hyphema was the most prevalent complication and nearly one in every four eyes would experience  $\geq 1$  mm hyphema. However, studies showed postoperative hyphema might indicate a better IOP control after CP, as it might be associated with restored aqueous outflow system [17, 37]. Descemet membrane detachment (DMD) was not a common complication after CP with an incidence of 3% in this review, and most DMD could be resolved without longlasting sequelae and its risk might be decreased by avoiding excessive injection into the Schlemm canal during viscodilation [38]. However, one 86-year-old man was reported to develop keratoplasty-needing corneal decompensation from DMD after CP [38].

Comparing complications between CP and TE, hyphema was more common in CP, but might be a good indicator for CP as mentioned before. DMD was only reported in CP and could be related to the Schlemm canal injection [38]. Hypotony and choroidal effusion/detachment were more common in TE than in CP, which was in agreement with former research [3]. In TE, hypotony might be the result of high filtration, while choroidal effusion often occurred with hypotony. Suprachoroidal hemorrhage, a severe complication, was only reported in TE with an incidence of 2.3% in this review [10, 33]. Bleb needling was an intervention reported in 10.9% of eyes after TE and in no eyes after CP as an NPS. To sum up, TE was associated with more complications than CP.

CP was reported with higher patient satisfaction than TE in a multiquestionnaire study conducted two years after surgery [39]. Another cost-effectiveness study indicated that although the surgery fee was higher in CP, the longer hospitalization, higher readmission rates, and more frequent postoperative interventions of TE displayed opportunity costs [13], which should be taken into consideration.

In the sensitivity analysis, the outcomes of the metaanalysis of the reductions in IOP and AGMs after CP were robust, especially after removing small weight studies. The publication bias might exist with missing studies on the left hand side of the funnel plots of IOP reduction at 6 months (Online Resource Figure 5) and 12 months (Online Resource Figure 6) after surgery [8]. In the quality assessment of the enrolled 6 studies comparing CP with TE, the RCT [22] showed higher risk of performance, detection, and attrition bias (Online Resource Figure 7). For the other 5 retrospective studies, the main problem existed in the selection of the controls (Online Resource Table 2), as clinical heterogeneity might exist between the CP cases and the TE controls.

One main limitation of this system review was the quality of the enrolled studies. Without limitation of research types as few RCTs were available, 18 of the 28 eligible literatures were retrospective studies, a study type with relatively low evidence level. Moreover, not many studies about the comparison between CP and TE were available, and only 1 was an RCT and the other 5 were retrospective. Another limitation was no unpublished data were enrolled in this review while the funnel plot indicated publication bias might exist.

# 5. Conclusion

CP was less effective in IOP reduction than TE, but CP was able to achieve similar postoperative success rates and reduce the number of the AGMs likewise. CP was also associated with lower incidence of complications and was reported with higher patient satisfaction. More high-quality studies, especially properly designed RCTs, are needed to verify our findings in this system review.

#### **Conflicts of Interest**

The authors declare that they have no conflicts of interest.

# Acknowledgments

This study is funded by the National Major Scientific Equipment program (Grant no. 2012YQ12008005).

#### References

- Collaborative Normal-Tension Glaucoma Study Group, "Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures," *American Journal of Ophthalmology*, vol. 126, no. 4, pp. 487–497, 1998.
- [2] D. F. Garway-Heath, D. P. Crabb, C. Bunce et al., "Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial," *Lancet*, vol. 385, no. 9975, pp. 1295–1304, 2015.
- [3] E. Rulli, E. Biagioli, I. Riva et al., "Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a

systematic review and meta-analysis," *JAMA Ophthalmology*, vol. 131, no. 12, pp. 1573–1582, 2013.

- [4] N. S. Borisuth, B. Phillips, and T. Krupin, "The risk profile of glaucoma filtration surgery," *Current Opinion in Ophthalmology*, vol. 10, no. 2, pp. 112–116, 1999.
- [5] N. Koerber, "Canaloplasty a new approach to nonpenetrating glaucoma surgery," *Techniques in Ophthalmology*, vol. 5, no. 3, pp. 102–106, 2007.
- [6] J. P. T. Higgins and S. Green, Cochrane handbook for systematic reviews of interventions version 5.1.0, 2011, February 2016, http://handbook.cochrane.org/.
- [7] C. Lommatzsch, C. Heinz, A. Heiligenhaus, and J. M. Koch, "Canaloplasty in patients with uveitic glaucoma: a pilot study," *Graefe's Archive for Clinical and Experimental Ophthalmology*, vol. 254, no. 7, pp. 1325–1330, 2016.
- [8] J. A. C. Sterne, A. J. Sutton, J. P. A. Ioannidis et al., "Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials," *British Medical Journal*, vol. 343, p. d4002, 2011.
- [9] G. A. Wells, D. O'Connell, J. Peterson, V. Welch, M. Losos, and P. Tugwell, *The Newcastle-Ottawa Scale (NOS) for asses*sing the quality of nonrandomised studies in meta-analyses, 2014, March 2016, http://www.ohri.ca/programs/clinical\_ epidemiology/oxford.asp.
- [10] R. S. Ayyala, A. L. Chaudhry, C. B. Okogbaa, and D. Zurakowski, "Comparison of surgical outcomes between canaloplasty and trabeculectomy at 12 months' follow-up," *Ophthalmology*, vol. 118, no. 12, pp. 2427–2433, 2011.
- [11] H. S. Barnebey, "Canaloplasty with intraoperative low dosage mitomycin C: a retrospective case series," *Journal of Glaucoma*, vol. 22, no. 3, pp. 201–204, 2013.
- [12] L. M. Brandao, A. Schotzau, and M. C. Grieshaber, "Suture distension of Schlemm's canal in canaloplasty: an anterior segment imaging study," *Journal of Ophthalmology*, vol. 2015, p. 457605, 2015.
- [13] A. Bruggemann and M. Muller, "Trabeculectomy versus canaloplasty - utility and cost-effectiveness analysis. [German]," *Klinische Monatsblätter für Augenheilkunde*, vol. 229, no. 11, pp. 1118–1123, 2012.
- [14] P. Brusini, "Canaloplasty in open-angle glaucoma surgery: a four-year follow-up," *Scientific World Journal*, vol. 2014, Article ID 469609, p. 7, 2014.
- [15] S. A. Gandolfi, N. Ungaro, S. Ghirardini, M. G. Tardini, and P. Mora, "Comparison of surgical outcomes between canaloplasty and Schlemm's canal scaffold at 24 Months' follow-up," *Journal of Ophthalmology*, vol. 2016, p. 3410469, 2016.
- [16] M. C. Grieshaber, A. Pienaar, J. Olivier, and R. Stegmann, "Canaloplasty for primary open-angle glaucoma: long-term outcome," *The British Journal of Ophthalmology*, vol. 94, no. 11, pp. 1478–1482, 2010.
- [17] M. C. Grieshaber, A. Schoetzau, J. Flammer, and S. Orgul, "Postoperative microhyphema as a positive prognostic indicator in canaloplasty," *Acta Ophthalmologica*, vol. 91, no. 2, pp. 151–156, 2013.
- [18] M. C. Grieshaber, H. R. Grieshaber, and R. Stegmann, "A new expander for Schlemm Canal surgery in primary open-angle glaucoma-interim clinical results," *Journal of Glaucoma*, vol. 25, no. 8, pp. 657–662, 2016.
- [19] E. Kalin-Hajdu, K. Hammamji, S. Gagne, and P. Harasymowycz, "Outcome of viscodilation and tensioning of Schlemm's canal

for uveitic glaucoma," *Canadian Journal of Ophthalmology*, vol. 49, no. 5, pp. 414–419, 2014.

- [20] R. A. Lewis, K. von Wolff, M. Tetz et al., "Canaloplasty: three-year results of circumferential viscodilation and tensioning of Schlemm canal using a microcatheter to treat open-angle glaucoma," *Journal of Cataract and Refractive Surgery*, vol. 37, no. 4, pp. 682–690, 2011.
- [21] I. Lopes-Cardoso, F. Esteves, M. Amorim, G. Calvao-Santos, M. L. Freitas, and J. Salgado-Borges, "Circumferential viscocanalostomy with suture tensioning in Schlemm canal (canaloplasty)-one year experience. [Spanish]," Archivos de la Sociedad Española de Oftalmología, vol. 88, no. 6, pp. 207–215, 2013.
- [22] J. Matlach, C. Dhillon, J. Hain, G. Schlunck, F. Grehn, and T. Klink, "Trabeculectomy versus canaloplasty (TVC study) in the treatment of patients with open-angle glaucoma: a prospective randomized clinical trial," *Acta Ophthalmologica*, vol. 93, no. 8, pp. 753–761, 2015.
- [23] M. Matthaei, J. Steinberg, A. Wiermann, G. Richard, and M. Klemm, "Canaloplasty: a new alternative in nonpenetrating glaucoma surgery. [German, English]," *Der Ophthalmologe*, vol. 108, no. 7, pp. 637–643, 2011.
- [24] M. C. Moelle, C. Cursiefen, R. Rejdak, F. K. Horn, and A. G. Junemann, "Time course of induced astigmatism after canaloplasty," *Journal of Glaucoma*, vol. 23, no. 1, pp. e53–e59, 2014.
- [25] A. M. Seuthe, C. Ivanescu, S. Leers, K. Boden, K. Januschowski, and P. Szurman, "Modified canaloplasty with suprachoroidal drainage versus conventional canaloplasty-1-year results," *Graefe's Archive for Clinical and Experimental Ophthalmology*, vol. 254, no. 8, pp. 1591–1597, 2016.
- [26] L. Thederan, F. Grehn, and T. Klink, "Comparison of canaloplasty with trabeculectomy. [German]," *Klinische Monatsblätter für Augenheilkunde*, vol. 231, no. 3, pp. 256–261, 2014.
- [27] B. Voykov, G. Blumenstock, M. A. Leitritz, S. Dimopoulos, and O. Alnahrawy, "Treatment efficacy and safety of canaloplasty for open-angle glaucoma after 5 years," *Clinical & Experimental Ophthalmology*, vol. 43, no. 8, pp. 768–771, 2015.
- [28] N. Wang, H. Wang, J. Hong et al., "The comparison of shortterm outcome between aqueous drainage pathway reconstruction surgery versus canaloplasty for open angle glaucoma. [Chinese]," *Chinese Journal of Ophthalmology*, vol. 50, no. 5, pp. 338–342, 2014.
- [29] C. Xin, X. Chen, Y. Shi, H. Wang, and N. Wang, "Modified canaloplasty: a new, effective, and safe option for glaucoma patients with a disrupted Schlemm Canal wall," *Journal of Glaucoma*, vol. 25, no. 10, pp. 798–801, 2016.
- [30] S. N. Arthur, L. B. Cantor, D. WuDunn et al., "Efficacy, safety, and survival rates of IOP-lowering effect of phacoemulsification alone or combined with canaloplasty in glaucoma patients," *Journal of Glaucoma*, vol. 23, no. 5, pp. 316–320, 2014.
- [31] J. Matlach, F. J. Freiberg, S. Leippi, F. Grehn, and T. Klink, "Comparison of phacotrabeculectomy versus phacocanaloplasty in the treatment of patients with concomitant cataract and glaucoma," *BMC Ophthalmology*, vol. 13, p. 1, 2013.
- [32] M. Rekas, A. Byszewska, K. Petz, J. Wierzbowska, and A. Junemann, "Canaloplasty versus non-penetrating deep sclerectomy - a prospective, randomised study of the safety and efficacy of combined cataract and glaucoma surgery; 12-month follow-up," *Graefe's Archive for Clinical and Experimental Ophthalmology*, vol. 253, no. 4, pp. 591–599, 2015.

- [33] E. D. Schoenberg, A. L. Chaudhry, R. Chod, D. Zurakowski, and R. S. Ayyala, "Comparison of surgical outcomes between phacocanaloplasty and phacotrabeculectomy at 12 Months' follow-up: a longitudinal cohort study," *Journal of Glaucoma*, vol. 24, no. 7, pp. 543–549, 2015.
- [34] S. A. Alobeidan and F. A. Almobarak, "Incidence and management of haemorrhagic Descemet membrane detachment in canaloplasty and phacocanaloplasty," *Acta Ophthalmologica*, vol. 94, no. 5, 2015.
- [35] K. Fujita, K. Kitagawa, Y. Ueta, T. Nakamura, A. Miyakoshi, and A. Hayashi, "Short-term results of canaloplasty surgery for primary open-angle glaucoma in Japanese patients," *Case Reports in Ophthalmology*, vol. 2, no. 1, pp. 65–68, 2011.
- [36] M. Rekas, M. E. Danielewska, A. Byszewska et al., "Assessing efficacy of canaloplasty using continuous 24-hour monitoring of ocular dimensional changes," *Investigative Ophthalmology* & Visual Science, vol. 57, no. 6, pp. 2533–2542, 2016.
- [37] J. M. Koch, A. Heiligenhaus, and C. Heinz, "Canaloplasty and transient anterior chamber haemorrhage: a prognostic factor? [German]," *Klinische Monatsblätter für Augenheilkunde*, vol. 228, no. 5, pp. 465–467, 2011.
- [38] A. Jaramillo, J. Foreman, and R. S. Ayyala, "Descemet membrane detachment after canaloplasty: incidence and management," *Journal of Glaucoma*, vol. 23, no. 6, pp. 351– 354, 2014.
- [39] T. Klink, J. Sauer, N. J. Korber et al., "Quality of life following glaucoma surgery: canaloplasty versus trabeculectomy," *Clinical Ophthalmology*, vol. 9, pp. 7–16, 2015.